Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608454 | 1.00 | POLA1 (0.74) | POLA1KCNH2 | |
| SCHEMBL6610700 | 1.00 | POLA1 (0.74) | POLA1KCNH2 | |
| SCHEMBL6610913 | 0.94 | POLA1 (0.79) | POLA1KCNH2 | |
| SCHEMBL6623478 | 0.94 | POLA1 (0.79) | POLA1KCNH2 | |
| SCHEMBL6622677 | 0.90 | POLA1 (0.72) | POLA1KCNH2 | |
| SCHEMBL6609485 | 0.90 | POLA1 (0.68) | POLA1KCNH2 | |
| SCHEMBL6623161 | 0.90 | POLA1 (0.73) | POLA1 | |
| SCHEMBL6624460 | 0.88 | POLA1 (0.72) | POLA1 | |
| SCHEMBL7117601 | 0.88 | POLA1 (0.72) | POLA1 | |
| SCHEMBL6620990 | 0.88 | POLA1 (0.75) | POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | claimed |
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207877-A1 | Pyridoquinoxaline antivirals | IFNAR1, SARS1, ZC3HAV1 | POLA1 401/4885KCNH2 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.